Shandong Sinobioway Biomedicine Co Ltd
SZSE:002581
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
7.91
16.96
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Shandong Sinobioway Biomedicine Co Ltd
Cash & Cash Equivalents
Shandong Sinobioway Biomedicine Co Ltd
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Shandong Sinobioway Biomedicine Co Ltd
SZSE:002581
|
Cash & Cash Equivalents
¥394.4m
|
CAGR 3-Years
22%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-1%
|
|
|
Fufeng Group Ltd
HKEX:546
|
Cash & Cash Equivalents
¥9.8B
|
CAGR 3-Years
84%
|
CAGR 5-Years
44%
|
CAGR 10-Years
N/A
|
|
|
G
|
GHW International
HKEX:9933
|
Cash & Cash Equivalents
¥77.4m
|
CAGR 3-Years
8%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Ningxia Baofeng Energy Group Co Ltd
SSE:600989
|
Cash & Cash Equivalents
¥5.1B
|
CAGR 3-Years
32%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
Zhejiang XinAn Chemical Industrial Group Co Ltd
SSE:600596
|
Cash & Cash Equivalents
¥4.2B
|
CAGR 3-Years
29%
|
CAGR 5-Years
29%
|
CAGR 10-Years
26%
|
|
|
A
|
Anhui Jinhe Industrial Co Ltd
SZSE:002597
|
Cash & Cash Equivalents
¥2.3B
|
CAGR 3-Years
5%
|
CAGR 5-Years
5%
|
CAGR 10-Years
16%
|
|
Shandong Sinobioway Biomedicine Co Ltd
Glance View
Shandong Sinobioway Biomedicine Co., Ltd. engages in the research and development, manufacture, and sale of chemical raw materials, chemical and pharmaceutical products. The company is headquartered in Beijing, Beijing and currently employs 653 full-time employees. The company went IPO on 2011-05-20. The firm's main products include encyclopedia, anferon, triethyl orthoformate, trimethyl orthofomate, trimethyl orthoacetate and related secondary products, among others. The firm distributes its products within domestic market and to overseas markets.
See Also
What is Shandong Sinobioway Biomedicine Co Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
394.4m
CNY
Based on the financial report for Jun 30, 2024, Shandong Sinobioway Biomedicine Co Ltd's Cash & Cash Equivalents amounts to 394.4m CNY.
What is Shandong Sinobioway Biomedicine Co Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
-1%
Over the last year, the Cash & Cash Equivalents growth was 794%. The average annual Cash & Cash Equivalents growth rates for Shandong Sinobioway Biomedicine Co Ltd have been 22% over the past three years , -19% over the past five years , and -1% over the past ten years .
You don't have any saved screeners yet
